You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...
3don MSN
Prices cut for popular obesity treatment, but doctors still see cost challenges for patients
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...
Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...
The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...
In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid ...
Some doctors are prescribing weight-loss drugs such as Zepbound and Ozempic to help reduce cravings for illicit drugs and ...
U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss ...
Novo Nordisk A/S is undercutting archrival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback